First test of new asthma antibody begins
NCT ID NCT07330778
Summary
This is a very early, first-in-human study to see if a new drug called CDX-622 is safe for people with mild to moderate asthma. Twelve participants will receive one dose via an IV infusion and be followed for 12 weeks. The main goal is to check for side effects and see how the drug moves through and affects the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD TO MODERATE ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Kansas Medical Center
RECRUITINGKansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.